Assessing symptom severity in patients with markedly treatment-resistant depression: Insights from the RECOVER trial
Clinical Snapshot
PICO Framework
| P — Population | Patients with markedly treatment-resistant depression (TRD) |
| I — Intervention | Adjunctive active vagus nerve stimulation (VNS) |
| C — Comparator | Adjunctive sham vagus nerve stimulation |
| O — Outcomes | Depression symptom severity measured by MADRS, QIDS-C, and QIDS-SR scales; psychometric properties including sensitivity to change, between-group discrimination, and response detection |
Bottom Line
This 12-month randomised sham-controlled trial of vagus nerve stimulation in treatment-resistant depression provides valuable insights into depression rating scale performance. The study found that while MADRS, QIDS-C, and QIDS-SR all demonstrated good psychometric properties, MADRS was less sensitive to detecting symptom changes and treatment differences. Five core symptom domains—mood, energy, interest, negative self-view, and concentration—emerged as most sensitive to therapeutic change across all scales. For Australian clinicians managing treatment-resistant depression, these findings suggest QIDS scales may be preferable to MADRS for monitoring treatment response. However, the abstract lacks crucial methodological details including sample size, completion rates, and actual clinical efficacy outcomes. While the psychometric findings are methodologically sound, clinicians should await full publication for comprehensive efficacy and safety data before making treatment decisions about VNS in treatment-resistant depression.
Key Findings
P Value: Not reported in abstract
Effect Size: Five core symptom domains (mood, energy, interest, negative self-view, concentration) showed largest effect sizes for detecting therapeutic change
Primary Outcome: Psychometric properties of depression rating scales in treatment-resistant depression
Nnt Or Sensitivity: MADRS demonstrated lower sensitivity for detecting overall and between-group symptom differences compared to QIDS-C and QIDS-SR
Confidence Interval: Not reported in abstract
Clinical Application
High - all three scales (MADRS, QIDS-C, QIDS-SR) are widely available and validated tools in Australian practice VNS is TGA-approved for treatment-resistant depression; findings support use of QIDS scales over MADRS for monitoring treatment response in Australian TRD patients; relevant for specialist psychiatrists and mood disorder clinics Patients with markedly treatment-resistant depression in tertiary psychiatric settings
Abstract
BACKGROUND: The performances of the Montgomery-Åsberg Depression Rating Scale (MADRS) and the Quick Inventory of Depressive Symptomatology-Clinician (QIDS-C) and Self-Report (QIDS-SR) ratings have never been evaluated in markedly treatment-resistant depression (TRD). RECOVER, a 12-month randomized, controlled trial, compared adjunctive active to adjunctive sham vagus nerve stimulation, provided data to address this knowledge gap, and to examine the basis for the differential sensitivities of these scales in detecting overall and between-treatment-group symptom changes. METHODS: We employed classical test and item response theory methods to characterize each scale. Effect sizes identified items that were most sensitive to change over time across treatments, best discriminated between the two treatments, and best detected at least a partial symptom response in clinician global ratings. RESULTS: All three inventories were unidimensional, with high retest reliability and strong internal consistency. MADRS total scores were less sensitive in detecting overall and between-treatment-group symptom differences. On each scale, five symptom domains-mood, energy/lassitude, interest/inability to feel, negative self-view/pessimism, and concentration-covaried most strongly with overall depression severity and had the largest effect sizes in detecting overall therapeutic change and between-group difference in efficacy. LIMITATIONS: These findings may not generalize to less treatment-resistant populations or to different treatments. The relative insensitivity of suicidal ideation, sleep, and appetite items may be due to study design or concomitant medications. CONCLUSION: The MADRS, QIDS-C, and QIDS-SR are suitable for use in markedly TRD. Whether sadness, energy, interest, guilt, and concentration are "core" symptoms that are especially sensitive to change deserves further study.
References
- 1.Rush, A. J., Sackeim, H. A., Lee, Y. C., Conway, C. R., Aaronson, S. T., Bunker, M. T., Quevedo, J., Alva, G., & Carmody, T. (2026). Assessing symptom severity in patients with markedly treatment-resistant depression: Insights from the RECOVER trial. Journal of Affective Disorders, 121447. https://doi.org/10.1016/j.jad.2026.121447
Related Research
Journal of psychiatric research
Systematic review of machine learning and deep learning models for EEG-based detection of depression.
2 Aug 2026
Sleep medicine reviews
Artificial intelligence in sleep medicine I: Diagnosis, treatment, care, and research
2 Aug 2026
International journal of yoga therapy
Randomized Controlled Trial on the Effect of Yoga on Anxiety Severity, Quality of Life, and Biomarkers in Individuals with Anxiety Disorder
31 July 2026
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service